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INTRODUCTION
The human body is potentially so highly nutritious that
it can well nourish some bacteria. However, it maintains an
iron-restricted condition, as most iron is bound to iron-with-
holding glycoproteins such as transferrin and lactoferrin, or
is sequestered within cells. This low iron-availability pro-
vides a non-specific defense mechanism that limits bacterial
growth within the human body. Conversely, in order for bac-
teria to grow within the human body, they must be able to
acquire iron effectively. For this purpose, most bacteria have
developed their specific high-affinity iron-uptake systems.
Among these systems, the siderophore-mediated iron-uptake
system is basic and essential in most bacteria (1, 2). The recent
increase in the incidence of infections caused by multidrug-
resistant bacteria including staphylococci, underlines the im-
portance of identifying novel preventive or therapeutic agents.
Bacterial iron-uptake systems are attractive targets for the
development of preventive or therapeutic vaccines, especial-
ly for multidrug-resistant bacteria. Similarly, iron-chelation
therapies capable of preventing bacterial iron-uptake have
also received attention as attractive novel preventive or ther-
apeutic modalities (3-7). 
In vivo iron-availability increases under some pathological
conditions. In vivo bacterial growth can be stimulated by
increased iron-availability, and conversely, bacterial growth
can be suppressed by reducing iron-availability. Coagulase-
negative staphylococci (CoNS), especially S. epidermidis, are
known to be major causative agents of septicemia in patients
who have received anticancer chemotherapy or stem cell trans-
plantation, because serum iron levels are elevated in these
patients (8-10). Recently, it was reported that S. epidermidis
infections in such patients can be prevented by administer-
ing human apotransferrin, which is a major iron-withhold-
ing protein (11). Moreover, it was reported that the growth
of coagulase-positive Staphylococcus aureus in human serum is
suppressed by administrating lactoferrin, another iron-with-
holding protein (12). These findings suggest a possibility
that chemical iron-chelating agents can also be used to pre-
vent staphylococcal infections, as well as to improve iron over-
load in such patients. 
Deferoxamine (C25H48N6O8∙CH4O3S) is the best known
hydroxamate siderophore derived from Streptomyces pilosus,
and is currently being used as the standard parenteral iron-
chelator for the treatment of iron-overload (13). In addition,
deferoxamine is known to have an antimicrobial effect, main-
ly because it competes with bacteria for available iron (14). In
vitro studies have demonstrated that deferoxamine has bac-
teriostatic activity against some pathogenic bacteria includ-
ing S. epidermidis, especially in the presence of ascorbic acid
(14-18). However, one of the drawbacks of deferoxamine is
that some pathogenic bacteria, including Yersinia enterocoliti-
ca, Vibrio vulnificus and S. aureus, are able to utilize the drug
for iron-uptake, in the same manner as they use their own
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Effect of Iron-Chelator Deferiprone on the In Vitro Growth of 
Staphylococci 
The standard iron-chelator deferoxamine is known to prevent the growth of coagu-
lase-negative staphylococci (CoNS) which are major pathogens in iron-overloaded
patients. However, we found that deferoxamine rather promotes the growth of coag-
ulase-positive Staphylococcus aureus. Accordingly, we tested whether deferiprone,
a new clinically-available iron-chelator, can prevent the growth of S. aureus strains
as well as CoNS. Deferiprone did not at least promote the growth of all S. aureus
strains (n=26) and CoNS (n=27) at relatively low doses; moreover, it could signifi-
cantly inhibit the growth of all staphylococci on non-transferrin-bound-iron and the
growth of all CoNS on transferrin-bound iron at relatively high doses. At the same
doses, it did not at least promote the growth of all S. aureus strains on transferrin-
bound-iron. These findings indicate that deferiprone can be useful to prevent staphy-
lococcal infections, as well as to improve iron overload, in iron-overloaded patients. 
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Accepted : 17 June 2008siderophores via specific receptors (19-23). This cautions that
deferoxamine therapy in iron-overloaded patients can facili-
tate fatal infections caused by Y. enterocolitica, V. vulnificus and
S. aureus.
Recently, a new synthetic oral iron-chelator deferiprone
(1,2-dimethyl-3-hydroxypyrid-4-one) became clinically avail-
able (24, 25). Deferiprone forms strong complexes with iron
at physiological pH. Deferiprone captures iron in vitro from
transferrin, lactoferrin, ferritin, and hemosiderin, and in vivo
after its parenteral or intragastric administration, and the
effect of deferiprone is similar to or greater than that of par-
enteral deferoxamine. Moreover, deferiprone has been found
to inhibit the growths of Y. enterocolitica and V. vulnificus capa-
ble of utilizing deferoxamine because structurally it is com-
pletely unlike deferoxamine (20, 26). However, whether
deferiprone can inhibit or facilitate the growth of staphylococ-
ci, especially S. aureus, has not been determined yet. Accord-
ingly, in this study, we determined the effect of deferiprone
on the in vitro growth of staphylococci. 
MATERIALS AND METHODS
Bacterial strains, media and reagents 
S. aureus KCTC1927 (ACTC6538), S. epidermidis KCTC-
1917 (ACTC12228) and S. saprophyticus KCTC3345 (ACTC-
15305) strains were purchased from the Korean Collection
for Type Cultures (http://kctc.kribb.re.kr/). CoNS (n=25) and
S. aureus strains (n=25) isolated from various clinical samples
were used in this study. Production of coagulase was tested
using Staphaurex Plus kits (Murex Biotech Limited, Dart-
ford, U.K.). CoPS included methicillin-susceptible strains
(n=11) and methicillin-resistant strains (n=14). Brain Heart
Infusion (BHI, BD, Sparks, MD, U.S.A.) agar was used to
subculture all staphylococci. Staphylococcal siderophore detec-
tion (SSD) medium, which was recommended as a minimal
medium containing low phosphate and citrate for studying
staphylococcal iron-uptake systems (27), was used without
deferration, because its iron concentration was less than 1 μ g/
dL (28). When necessary, 1 μ M of ferric chloride (FC) as a
non-transferrin-bound-iron source or 0.5 mg/mL of human
holotransferrin (HT; 1,200-1,600 μ g of iron per 1 g of pro-
tein) as a transferrin-bound-iron source was added to SSD
agars or broths. Deferoxamine was purchased from Ciba-
Geigy (Basel, Switzerland) and deferiprone from Apotex Inc.
(Toronto, Canada). Unless otherwise noted, all reagents were
purchased from Sigma (Sparks, MO, U.S.A.). 
Observations of the effect of deferoxamine on staphylo-
coccal growth 
Staphylococci were preconditioned in BHI broth contain-
ing 200 μ M dipyridyl, an iron chelator, at 37℃ overnight
in order to adapt them to iron-restricted conditions and to
reduce intracellular iron stores. In order to observe the effect
of deferoxamine on staphylococcal growth, about 1×104 cfu
of the preconditioned staphylococci were spread onto SSD agars
supplemented with 1 μ M FC (or 0.5 mg/mL HT). Paper discs
containing 30 μ L of deferoxamine solution (100 μ M) or phos-
phate-buffered saline were then placed on agar surfaces. Be-
cause S. aureus strains generally grew more rapidly than CoNS
on SSD agars, we observed S. aureus growths after 24 hr but
CoNS growths after 48 hr. Response to deferoxamine was
determined by the presence of a growth-stimulatory zone or
290 C.-M. Kim and S.-H. Shin
Fig. 1. Examples of responses of staphylococci to deferoxamine.
Staphylococcus aureus KCTC1927, Staphylococcus epidermidis
KCTC1917, Staphylococcus saprophyticus KCTC3345 and a
coagulase-negative staphylococcus (CoNS: S. epidermidis) strain
were preconditioned by culturing in BHI broth containing 200 μ M
of dipyridyl at 37。 C overnight to adapt to iron-restricted conditions
and to reduce intracellular iron stores. About 10
3-4 cfu of these
three strains were spread onto the surface of SSD agar contain-
ing 1 μ M FeCl3, and then discs containing 30 μ L of phosphate-
buffered saline (PBS) or 100 μ M deferoxamine were placed on
the agar surface. S. aureus KCTC1927 was incubated at 37。 C for
24 hr, and S. epidermidis KCTC1917, S. saprophyticus KCTC3345
and the CoNS strain for 48 hr. 
PBS
S. aureus
S. epidermidis
S. saprophyticus
CoNS
Deferoxaminea growth-inhibitory zone around discs containing deferox-
amine, as shown in Fig. 1. 
Observations of the effect of deferiprone on staphylococ-
cal growths 
Staphylococci, preconditioned as above, were inoculated into
SSD broths containing 1 μ M FC (or 0.5 mg/mL HT) or into
SSD broths containing 1 μ M FC (or 0.5 mg/mL HT) plus
0.5-1.5 mM deferiprone at about 1×106 cfu/mL, and then
cultured with vigorous shaking (220 rpm) for 6 hr or 24 hr
at 37℃. During culture, aliquots were withdrawn at appro-
priate times, and bacterial growths were measured by opti-
cal densities at a wavelength of 600 nm (OD600). Response to
deferiprone was determined by comparing the OD600 ratios
of strains after culture for 6 hr in broths with/without deferi-
prone. Response was arbitrarily expressed using OD ratios,
as; less than 0.8 (growth inhibition), 0.8-1.2 (no response)
and more than 1.2 (growth stimulation). The responses of S.
aureus KCTC1927, S. epidermidis KCTC1917, and S. sapro-
phyticus KCTC3345 strains are presented as growth kinetics
over 24 hr. 
6 M urea-gel electrophoresis
During culture in SSD broths containing HT, culture
supernatants were obtained by centrifuging culture aliquots
obtained at appropriate times at 10,000 rpm for 5 min. Equal
volumes (20 μ L) of culture supernatants were reacted with
sample buffer containing 8 M urea, but not SDS or mercap-
toethanol, at 37℃ for 30 min, and then electrophoresed on
5% stacking gel and 6% running gel containing 6 M urea
(28). Proteins were visualized by staining with Coomassie
brilliant blue R-250. On 6 M urea-gel, transferrin molecules
are separated into four forms according to their iron-satura-
tion levels, i.e., apoferric (AP), C-terminal monoferric (MC),
N-terminal monoferric (MN), and diferric (DF) forms.
RESULTS 
We first tested the responses of staphylococci to deferoxamine
(Fig. 1, Table 1). The growth of S. aureus KCTC1927 was
enhanced but those of S. epidermidis KCTC1917 and S. sapro-
phyticus KCTC3345 were inhibited by deferoxamine. The
growths of 15 S. aureus strains were enhanced around discs
containing deferoxamine, but the other 10 strains did not
respond. No S. aureus strain showed ‘growth inhibition’ by
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Details were described in the section of Materials and Methods. Res-
ponse to deferoxamine was determined by the presence of a growth-
enhancing zone or a growth-inhibitory zone around a disc containing
deferoxamine as shown in Fig. 1. The experiment was repeated twice
and results were consistent.
CoNS, coagulase-negative staphylococci.
Bacteria
Response to deferoxamine
(number of strains)
Growth 
enhancement
No response
Growth
inhibition
S. aureus (n=25) 15 10 0
CoNS (n=25) 2 0 23 
Table 1. Responses of staphylococci to deferoxamine
Fig. 2. Effect of deferiprone on the growths of staphylococci on non-transferrin-bound iron. The preconditioned s KCTC1927, Staphylo-
coccus epidermidis KCTC1917 and Staphylococcus saprophyticus KCTC3345 strains were inoculated into SSD broth containing 1 μ M FC
or in SSD broth containing 1 μ M FC plus 0.5-1.5 mM deferiprone (DFP) at ca. 1×10
6 cfu/mL, and then cultured with vigorous shaking
(220 rpm) at 37。 C for 24 hr. During culture, aliquots were withdrawn at appropriate times, and bacterial growths were monitored by mea-
suring OD600 values. Results are expressed as means±standard errors.
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S. saprophyticusdeferoxamine. In contrast, only two CoNS (S. epidermidis)
strains showed ‘growth enhancement’ by deferoxamine, where-
as the growths of the remaining 23 strains were inhibited.
The response of one of the two CoNS strains to deferoxam-
ine was shown in the Fig. 1. Similar results were observed
when SSD broths containing HT plus deferoxamine were
used (data not shown). Moreover, the responses of S. aureus
strains to deferoxamine were not associated with their suscep-
tibilities to methicillin (data not shown). As shown in the
Fig. 1, some S. aureus and CoNS strains appeared to respond
to phosphate-buffered saline alone, indicating that they can
use phosphate for iron-uptake. 
To determine whether deferiprone can inhibit the growths
of staphylococci on non-transferrin-bound-iron, we cultured S.
aureus KCTC1927, S. epidermidis KCTC1917 and S. sapro-
phyticus KCTC3345 strains in SSD broths only, in SSD broths
containing 1 μ M FC, or in SSD broths containing 1 μ M FC
plus 0.5-1.5 mM deferiprone. The growths of the three stra-
ins were stimulated by the addition of FC (Fig. 2). S. aureus
KCTC1927 grew more actively than S. epidermidis KCTC-
1917 or S. saprophyticus KCTC3345 in iron-limited SSD
broths or in SSD broths containing FC. These growth stim-
ulations by FC were inhibited dose-dependently by deferi-
prone. Deferiprone showed a greater growth-inhibitory effect
against S. epidermidis KCTC1917 and S. saprophyticus KCTC-
3345 than against S. aureus KCTC1927. At less than 0.5
mM, deferiprone did not affect the growths of all the three
staphylococci; that is to say, it did not facilitate the growths
of all the three staphylococci in contrast with deferoxamine
(data not shown). 
To determine whether deferiprone inhibits the growths of
S. aureus (n=25) and CoNS (n=25) strains on non-transfer-
rin-bound-iron, we cultured all 50 staphylococci in SSD broths
containing 1 μ M FC or in SSD broths containing 1 μ M FC
plus 1.5 mM deferiprone at 37℃ for 6 hr. Deferiprone in-
hibited the growths of all S. aureus and CoNS strains on non-
transferrin-bound-iron regardless of the ability to utilize de-
feroxamine (Table 2) and methicillin susceptibility (data not
shown). 
To determine whether deferiprone can also inhibit the
growths of S. aureus KCTC1927, S. epidermidis KCTC1917
and S. saprophyticus KCTC3345 strains on transferrin-bound-
iron, we cultured these strains in SSD broths only, in SSD
broths containing 0.5 mg/mL HT or in SSD broths contain-
ing 0.5 mg/mL HT plus 0.5-1.5 mM deperiprone for 24 hr.
The growths of all three strains were stimulated by the addi-
tion of HT (Fig. 3). S. aureus KCTC1927 grew more active-
ly than S. epidermidis KCTC1917 or S. saprophyticus KCTC-
292 C.-M. Kim and S.-H. Shin
Details were described in the section of Materials and Methods. 
The experiment was repeated twice and results were consistent.
CoNS, coagulase-negative staphylococci.
Bacteria Iron sources
Response to deferiprone
(number of strains)
Growth 
enhancement
No
response
Growth
inhibition
S. aureus FeCl3 00 2 5
(n=25) Holotransferrin 0 25 0
CoNS FeCl3 0 0 25 
(n=25) Holotransferrin 0 0 25 
Table 2. Responses of staphylococci to deferiprone
Fig. 3. Effect of deferiprone on the growths of staphylococci on transferrin-bound iron. The preconditioned Staphylococcus aureus KCTC1927,
Staphylococcus epidermidis KCTC1917 and Staphylococcus saprophyticus KCTC3345 were inoculated into SSD broth containing 0.5 mg/
mL HT or in SSD broth containing 0.5 mg/mL HT plus 0.5-1.5 mM deferiprone (DFP) at ca. 1×10
6 cfu/mL, and then cultured with vigorous
shaking (220 rpm) at 37。 C for 24 hr. The other abbreviations and symbols are as in Fig. 2.
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S. saprophyticus
+HT+PBS +HT+0.5 mM DFP +PBS +HT+1.5 mM DFP3345 in SSD broths containing HT (Fig. 3), and it also uti-
lized iron from transferrin more efficiently than the other
two staphylococci (Fig. 4). On 6 M urea-gel electrophoresis,
transferrin bands were changed from DF to MN or MC to
AP forms as the result of the removal of iron from transfer-
rin molecules by staphylococci or deferiprone. The growth
stimulations of S. epidermidis KCTC1917 and S. saprophyticus
KCTC3345 by HT were inhibited dose-dependently by
deferiprone. In contrast, the growth stimulation of S. aureus
KCTC1927 by HT was not inhibited by deferiprone. As
shown at 0 hr in Fig. 4, deferiprone evidently reduced the
iron-saturation level of transferrin by removing iron from
diferric transferrin. Nevertheless, S. aureus KCTC1927 still
utilized iron from transferrin more efficiently than the other
two staphylococci. 
To determine whether deferiprone inhibits the growths of
S. aureus (n=25) and CoNS (n=25) strains on transferrin-
bound-iron, we cultured all 50 staphylococci in SSD broths
containing 0.5 mg/mL HT or in SSD broths containing 0.5
mg/mL HT plus 1.5 mM deferiprone at 37℃ for 6 hr. The
growths of all CoNS strains were inhibited by deferiprone.
In contrast, the growths of all S. aureus strains were not inhib-
ited by deferiprone. 
DISCUSSION
Hartzen et al. reported that deferoxamine can inhibit the
growths of staphylococci, especially in the presence of ascorbic
acid (16-18). However, according to our results, the respons-
es of staphylococci to deferoxamine appear to vary among staphy-
lococcal species and strains. Deferoxamine was found to stim-
ulate the growths of a few CoNS strains as well as of most S.
aureus strains (Table 1). Our results are supported by recent
reports, in which S. aureus was found to utilize deferoxamine
for iron-acquisition and growth via a specific ATP-binding
cassette (ABC) transporter system (23, 29). One iron-regu-
lated ABC transporter has also been reported in S. epidermidis
(30). However, it is not determined whether this transporter
system is involved in the uptake of deferoxamine-iron com-
plex by S. epidermidis. Overall, it appears that deferoxamine
therapy in patients with iron-overload can facilitate staphy-
lococcal infections, especially S. aureus infections. Moreover,
deferoxamine is known to stimulate the growths of other
pathogenic bacteria including Y. enterocolitica and V. vulnifi-
cus (19-22, 26). These problems severely limit the use of defer-
oxamine for the treatment of iron-overload, although the
drug has been used for some time as a standard iron-chela-
tor for the treatment of iron-overload (13).
S. aureus appear to possess more efficient iron-uptake sys-
tems than CoNS. In our previous studies (31-34), S. aureus
was found to acquire iron efficiently from partially iron-satu-
rated transferrin as well as highly iron-saturated transferrin,
whereas S. epidermidis and S. saprophyticus were able to acquire
iron only from highly iron-saturated transferrin, but less effi-
ciently than S. aureus. Lindsay et al. found that S. aureus is
able to actively grow and produce siderophores in severely
iron-limited SSD medium, whereas CoNS grew poorly and
did not produce siderophores (27). Trivier and Courcol report-
ed that S. aureus could grow in severely iron-limited media
containing 0.04 μ M Fe whereas other bacteria could not (35).
Martinaho et al. also found that the growth initiation of S.
epidermidis is dependent on the presence of readily-available
iron, i.e., non-transferrin-bound-iron (10). According to the
results of the present study, S. aureus grew more actively in
SSD broths containing FC or HT and utilized iron from trans-
ferrin more efficiently than S. epidermidis or S. saprophyticus
(Fig. 2-4). Similar results were observed for all S. aureus and
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Fig. 4. Utilization of transferrin-bound iron by staphylococci in the absence or presence of deferiprone. During culture in SSD broth con-
taining holotransferrin (HT) or in SSD broth containing HT plus deferiprone (DFP), as shown in Fig. 3, culture supernatants were obtained
by centrifuging culture aliquots at 10,000 rpm for 5 min at appropriate times. Equal volumes (20 μ L) of culture supernatants were elec-
trophoresed on 6 M urea-polyacrylamide gels, and stained with Coomassie blue. AP, MC, MN, and DF indicate apoferric, C-terminal mono-
ferric, N-terminal monoferric and diferric transferrins, respectively. 
AP
MC
MN +HT+PBS
DF
AP
MC
MN +HT+1.5 mM DFP
DF
0 3 6 9 12 24
S. aureus
0 3 6 9 12 24
S. epidermidis
0 3 6 9 12 24 (hr)
S. saprophyticusCoNS strains examined. In addition, deferiprone was found
to inhibit the growths of all CoNS strains, but not of S. aureus
strains, on transferrin-bound-iron. Overall, all these findings
indicate that S. aureus possess more efficient iron-uptake sys-
tems that enable them to grow more actively in severely iron-
limited conditions and to utilize transferrin-bound-iron more
efficiently than CoNS. 
CoNS, but not S. aureus, are known to be major causative
agents of septicemia in iron-overloaded patients who have
received anticancer chemotherapy or stem cell transplanta-
tion. CoNS growth proved to be stimulated by elevated non-
transferrin-bound-iron or transferrin-bound iron in such iron-
overloaded patients (8, 9). According to our results, deferip-
rone can inhibit significantly the growths of staphylococci,
especially CoNS, by reducing iron-availability at high doses;
moreover, at least it does not promote the growths of staphylo-
cocci, especially S. aureus, at low doses and on transferrin-bound-
iron. As shown in Fig. 4, the ability of deferiprone to remove
iron from transferrin in vitro and in vivo has been confirmed
independently by others under similar conditions (36-38).
Accordingly, deferiprone can be useful for the prevention of
CoNS infections along with the treatment of iron-overload by
reducing both the level of non-transferrin-bound-iron and the
iron-saturation level of transferrin. 
It has been reported that apotransferrin can prevent S. epi-
dermidis growth in patients with iron-overload (11) and that
lactoferrin or apotransferrin can prevent S. aureus growth in
human serum or human peritoneal dialysate (12, 32). How-
ever, our results show that S. aureus can still efficiently acquire
iron from low iron-saturated transferrin (Fig. 3, 4). In addi-
tion, apotransferrin and lactoferrin are inevitably destroyed
in vivo and must be administered intravenously because of
the proteineous natures. In contrast, deperiprone is a simple
chemical oral agent and thus is free of these limitations of
apotransferrin and lactoferrin (24, 25). 
It was reported that deferiprone can also inhibit the growth
of Y. enterocolitica by decreasing iron-availability (20). In addi-
tion, we recently found that deferiprone can also inhibit the
growth of V. vulnificus, which causes fatal septicemia with
an associated mortality rate of over 50% (26). Moreover, no
one has yet found a bacterium capable of utilizing deferiprone
for iron uptake. According to our results, deferiprone did not
promote the growths of staphylococci at less than 0.5 mM in
contrast with deferoxamine (data not shown). Relatively high-
er doses of deferiprone (>0.5 mM) were required to inhibit
the growths of staphylococci than those were required to inhibit
the growth of Y. enterocolitica or V. vulnificus (<0.2 mM). This
is attributed to the more efficient iron-uptake systems of
staphylococci, which enable them to more actively grow under
severely iron-limited conditions than Y. enterocolitica or V. vul-
nificus; the latter two are considered archetypal ferrophilic or
iron-sensitive bacteria that require higher levels of available
iron for growth than other bacteria (26, 39). Ascorbic acid
is known to enhance the efficacy of deferiprone as it does for
deferoxamine (14-18, 40). Accordingly, the deferiprone doses
required to inhibit the growths of staphylococci may be re-
duced by administering it in combination with ascorbic acid.
Also, more potent iron-chelators capable of efficiently inhibit-
ing the growth of staphylococci, especially S. aureus, are re-
quired (40). 
Overall, the present study indicates that, in contrast with
deferoxamine, deferiprone can inhibit the growths of staphy-
lococci, especially CoNS, by reducing iron-availability at rela-
tively high doses; moreover, at least it does not promote the
growths of staphylococci, especially S. aureus, at relatively low
doses. Accordingly, it is thought that deferiprone can be a
useful iron-chelator to prevent staphylococcal infections, as
well as to improve iron overload, in iron-overloaded patients.
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